Broken String Biosciences

Executive Summary

Broken String Biosciences is a UK-based biotechnology company that has developed INDUCE-seq®, a proprietary genome-wide platform for unbiased on- and off-target analysis in gene editing. The technology directly labels and captures DNA breaks in cells, providing empirical safety data that enables researchers to assess editing specificity entirely in-house. By replacing fragmented legacy workflows, INDUCE-seq accelerates the development of safer cell and gene therapies. Founded in 2020 and headquartered in Cambridge, the company addresses a critical bottleneck in the gene editing pipeline—the need for comprehensive, reliable off-target detection to meet regulatory standards and advance clinical programs. As the field of gene therapy expands, the demand for such analytical tools is increasing, positioning Broken String Biosciences as a key enabler for developers seeking to derisk their candidates and expedite time-to-market. With its innovative approach, the company is poised to capture significant market share in the preclinical safety assessment segment, supported by growing adoption among gene editing research institutions and biopharma partners.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• Q4 2026Peer-Reviewed Publication of INDUCE-seq Validation Data60% success
• Q4 2026Commercial Partnership with Top Gene Therapy Developer50% success